91.75MMarket Cap-1575P/E (TTM)
6.953High6.620Low154.81KVolume6.850Open6.790Pre Close1.05MTurnover1.41%Turnover RatioLossP/E (Static)13.80MShares22.49052wk High12.99P/B73.03MFloat Cap4.53052wk Low--Dividend TTM10.98MShs Float132.000Historical High--Div YieldTTM4.91%Amplitude2.418Historical Low6.784Avg Price1Lot Size
Annovis Bio Stock Forum
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
Annovis Bio Inc. (NYSE: ANVS) announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain, from October 29 to November 1, 2024. The presentations will highlight the progress of buntanetap, the company's drug candidate for neurodegenerative disorders like Alzheimer's and Parkinson's disease.
Dr. Maria...
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
Annovis Bio Inc. (NYSE: ANVS) has announced promising early research results for its lead drug, buntanetap, in combination with other approved drugs for Alzheimer's disease (AD) treatment. While recent FDA-approved drugs like Leqembi and Kisunla may slow cognitive decline in AD patients, they do not improve cognition. Similarly, GLP-1 drugs, origi...
Larger Image: tradingview.com...
$ANVS
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
Annovis Bio Inc. (NYSE: ANVS) has filed three new patents for innovative combination therapies involving its lead compound, buntanetap. These patents cover combinations of buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's.
Recent preclinical studies ...
No comment yet